<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>AI in Drug Development - Leading Companies</title>
    <link rel="stylesheet" href="styles.css">
</head>
<body>
    <header>
        <h1>AI in Drug Development</h1>
        <p>Leading Companies Revolutionizing Drug Discovery</p>
    </header>

    <div class="container">
        <div class="company-card">
            <h2>Insilico Medicine</h2>
            <div class="company-info">
                <strong>Founded:</strong> 2014<br>
                <strong>Location:</strong> Hong Kong/New York<br>
                <strong>CEO:</strong> Alex Zhavoronkov, Ph.D.<br>
                <strong>Total Funding:</strong> $424.3M (as of 2023)<br>
                <strong>Latest Valuation:</strong> >$1B (Unicorn status)
            </div>

            <div class="quick-stats">
                <div class="stat-box">
                    <strong>14</strong>
                    Drug Candidates
                </div>
                <div class="stat-box">
                    <strong>30+</strong>
                    Partnerships
                </div>
                <div class="stat-box">
                    <strong>200+</strong>
                    Peer-reviewed Publications
                </div>
            </div>

            <h3>Technology Platform</h3>
            <div class="tech-features">
                <div class="tech-feature">
                    <h4>PharmaAI</h4>
                    <p>End-to-end AI platform for drug discovery and development:</p>
                    <ul>
                        <li><strong>Chemistry42:</strong> De novo small molecule generation and optimization</li>
                        <li><strong>PandaOmics:</strong> AI-driven target discovery</li>
                        <li><strong>InClinico:</strong> Clinical trial outcome prediction</li>
                    </ul>
                </div>
            </div>

            <h3>Pipeline Highlights</h3>
            <div class="pipeline-section">
                <div class="pipeline-grid">
                    <div class="pipeline-item">
                        <strong>ISM001-055:</strong> Fibrosis treatment
                        <p>Status: Phase I Clinical Trials</p>
                    </div>
                    <div class="pipeline-item">
                        <strong>ISM003-268:</strong> Cancer treatment
                        <p>Status: IND-enabling studies</p>
                    </div>
                </div>
            </div>

            <h3>Key Partnerships</h3>
            <ul class="partnership-list">
                <li><strong>Sanofi:</strong> $1.2B deal for AI-driven drug development (2022)</li>
                <li><strong>Teva Pharmaceuticals:</strong> Strategic collaboration for AI drug discovery</li>
                <li><strong>Fosun Pharma:</strong> Joint development agreement for China market</li>
            </ul>

            <div class="market-position">
                <h3>Competitive Advantages</h3>
                <ul>
                    <li>End-to-end AI platform covering entire drug development process</li>
                    <li>Proven track record of rapid drug candidate discovery (weeks vs years)</li>
                    <li>Strong IP portfolio with multiple patents</li>
                    <li>Demonstrated success in bringing AI-discovered drugs to clinical trials</li>
                </ul>
            </div>
        </div>

        <div class="company-card">
            <h2>Atomwise</h2>
            <div class="company-info">
                <strong>Founded:</strong> 2012<br>
                <strong>Location:</strong> San Francisco, CA<br>
                <strong>CEO:</strong> Abraham Heifets<br>
                <strong>Total Funding:</strong> $174M<br>
                <strong>Latest Round:</strong> Series B (2020)
            </div>

            <div class="quick-stats">
                <div class="stat-box">
                    <strong>1000+</strong>
                    Projects
                </div>
                <div class="stat-box">
                    <strong>500+</strong>
                    Research Collaborations
                </div>
                <div class="stat-box">
                    <strong>17B+</strong>
                    Compounds Analyzed
                </div>
            </div>

            <h3>Technology Platform</h3>
            <div class="tech-features">
                <div class="tech-feature">
                    <h4>AtomNet Platform</h4>
                    <p>Deep learning platform for small molecule drug discovery:</p>
                    <ul>
                        <li>Structure-based drug design</li>
                        <li>Molecular property prediction</li>
                        <li>Hit discovery and optimization</li>
                        <li>Multi-parameter optimization</li>
                    </ul>
                </div>
            </div>

            <h3>Key Differentiators</h3>
            <div class="highlight-box">
                <ul>
                    <li>First to apply deep learning to drug discovery (2012)</li>
                    <li>Proprietary 3D deep learning architecture</li>
                    <li>Demonstrated success in finding novel binding sites</li>
                    <li>Proven ability to identify active compounds across diverse targets</li>
                </ul>
            </div>

            <h3>Notable Partnerships</h3>
            <ul class="partnership-list">
                <li><strong>Eli Lilly:</strong> Multi-target drug discovery collaboration</li>
                <li><strong>Hansoh Pharma:</strong> Strategic partnership for novel drug development</li>
                <li><strong>Bridge Biotherapeutics:</strong> Collaboration for drug discovery</li>
            </ul>
        </div>

        <div class="company-card">
            <h2>DeepMind (Isomorphic Labs)</h2>
            <div class="company-info">
                <strong>Founded:</strong> 2021 (Isomorphic Labs)<br>
                <strong>Location:</strong> London, UK<br>
                <strong>CEO:</strong> Demis Hassabis<br>
                <strong>Parent Company:</strong> Alphabet (Google)<br>
                <strong>Resources:</strong> Backed by Google's infrastructure
            </div>

            <div class="quick-stats">
                <div class="stat-box">
                    <strong>200M+</strong>
                    Protein Structures
                </div>
                <div class="stat-box">
                    <strong>92.4%</strong>
                    Prediction Accuracy
                </div>
                <div class="stat-box">
                    <strong>$1B+</strong>
                    Research Investment
                </div>
            </div>

            <h3>Core Technologies</h3>
            <div class="tech-features">
                <div class="tech-feature">
                    <h4>AlphaFold</h4>
                    <p>Revolutionary protein structure prediction system:</p>
                    <ul>
                        <li>Accurate 3D protein structure prediction</li>
                        <li>Protein-protein interaction modeling</li>
                        <li>Structure-based drug design capabilities</li>
                    </ul>
                </div>
                <div class="tech-feature">
                    <h4>Advanced AI Systems</h4>
                    <ul>
                        <li>Novel molecular design algorithms</li>
                        <li>Multi-scale biological modeling</li>
                        <li>Integration with experimental data</li>
                    </ul>
                </div>
            </div>

            <div class="market-position">
                <h3>Strategic Advantages</h3>
                <ul>
                    <li>Access to Google's computational resources and expertise</li>
                    <li>Built on DeepMind's proven AI capabilities</li>
                    <li>Integration with AlphaFold's breakthrough technology</li>
                    <li>Strong academic and research partnerships</li>
                </ul>
            </div>
        </div>

        <div class="company-card">
            <h2>BenevolentAI</h2>
            <div class="company-info">
                <strong>Founded:</strong> 2013<br>
                <strong>Location:</strong> London, UK<br>
                <strong>CEO:</strong> Joanna Shields<br>
                <strong>Market Cap:</strong> Listed on Euronext Amsterdam<br>
                <strong>Total Funding:</strong> >$292M (pre-IPO)
            </div>

            <div class="quick-stats">
                <div class="stat-box">
                    <strong>30+</strong>
                    Drug Programs
                </div>
                <div class="stat-box">
                    <strong>20+</strong>
                    Disease Areas
                </div>
                <div class="stat-box">
                    <strong>250+</strong>
                    Scientists & Engineers
                </div>
            </div>

            <h3>Technology Platform</h3>
            <div class="tech-features">
                <div class="tech-feature">
                    <h4>Benevolent Platform</h4>
                    <p>Integrated AI and machine learning platform:</p>
                    <ul>
                        <li>Knowledge Graph with billions of data points</li>
                        <li>Target identification and validation</li>
                        <li>Molecular design and optimization</li>
                        <li>Patient stratification</li>
                    </ul>
                </div>
            </div>

            <h3>Pipeline & Achievements</h3>
            <div class="pipeline-section">
                <div class="pipeline-grid">
                    <div class="pipeline-item">
                        <strong>BEN-2293:</strong> Atopic dermatitis
                        <p>Status: Phase I/II Clinical Trials</p>
                    </div>
                    <div class="pipeline-item">
                        <strong>AstraZeneca Collaboration:</strong> CKD & IPF
                        <p>Status: Multiple programs in development</p>
                    </div>
                </div>
            </div>

            <div class="market-position">
                <h3>Market Differentiation</h3>
                <ul>
                    <li>Public company with transparent operations</li>
                    <li>Proven success in COVID-19 drug repurposing</li>
                    <li>Strong focus on rare and complex diseases</li>
                    <li>Extensive validation through pharma partnerships</li>
                </ul>
            </div>
        </div>
    </div>

    <footer>
        <p>Last Updated: November 2024</p>
        <div class="disclaimer">
            <p>This competitive analysis is based on publicly available information and is intended for research purposes only. All data should be independently verified.</p>
        </div>
    </footer>

</body>
</html>